Brand New: BYHEALTH’s Protein Upgrade, MIRIQA’s Immunity Debut, Elevit and More

Why It Matters

These developments signal accelerating consumer demand for high‑quality, science‑backed nutrition across the Asia‑Pacific, reshaping distribution and product strategies for global supplement players.

Key Takeaways

• BYHEALTH raises protein content to 90% for Chinese market
• MIRIQA launches Immunity Builder jelly for families
• Vavitas introduces NMN, fish oil, D3+K2 longevity line
• Otsuka adds kaempferol supplement after 13 years research
• MyProtein rebounds despite record whey price spikes

Pulse Analysis

The protein boom in China is no longer limited to basic whey powders; consumers are seeking higher purity and functional benefits, prompting BYHEALTH to upgrade its Zhenzuan line to 90% protein. This move aligns with a broader shift toward premium nutrition, where brand credibility and scientific validation become key differentiators. Companies that can deliver higher‑grade ingredients while maintaining price competitiveness are poised to capture the expanding middle‑class market.

Immunity and longevity are emerging as the next growth frontiers. MIRIQA’s Immunity Builder jelly taps into family‑wide health stewardship, leveraging the popularity of its collagen jelly format. Simultaneously, Vavitas, founded by seasoned pharmacy entrepreneur Margarita Zhao, is targeting the anti‑aging segment with NMN, fish oil, and vitamin D3+K2 softgels, reflecting rising consumer willingness to invest in preventive supplements backed by scientific advisors.

Distribution dynamics are also evolving. Bayer’s Elevit uses partnership‑driven outreach to address Australian mothers’ emotional and physical challenges, while Swisse pivots to platforms like Douyin and Sam’s Club to offset declining brick‑and‑mortar sales in China. Otsuka’s launch of a kaempferol supplement under the /zeroz brand underscores the importance of novel bioactives, and MyProtein’s growth rebound despite record whey prices demonstrates that strong brand equity and agile supply‑chain management can mitigate raw‑material volatility. Collectively, these trends highlight a market where product innovation, targeted health claims, and digital channel adoption are reshaping the nutraceutical landscape.